熔融池氧化物层自然对流的数值模拟

本文以BALI试验段为对象建模,对其中有内热源的湍流自然对流流体进行了二维数值模拟。模拟工况的瑞利数Ra高达10¹²～10¹⁵。流体的湍流运动用大涡模拟模型来捕捉。通过对下边界局部热流密度的面积加权积分,计算了三维下边界换热量。结果表明,Ra对流场、温度场与下边界局部热流密度分布均有显著影响。计算所得上下边界的Ra-Nu关系与试验结果符合较好。对不同物理机理导致的下边界热流密度分布规律进行了分析。     

中国大陆进口冷链食品关联新型冠状病毒疫情调查

目的 新型冠状病毒（SARS-CoV-2）全球大流行以来,中国大陆报道了多起SARS-CoV-2污染进口冷链食品引起的本土新冠疫情,分析此类疫情的特点和传播概况,可以为今后类似疫情防控提出相应建议。方法 收集SARS-CoV-2污染进口冷链食品引起本土新冠疫情文献、官方新闻报道等信息,整理和分析相应数据。结果 2020年6月至2022年11月,共检索到此类疫情20起,包含1 646例病例,涉及9个省（自治区、直辖市）。其中,2020年10起,2021年3起,2022年7起;病例数规模在200例及以上共3起。结论 新冠全球大流行以来中国大陆检索到的20起进口冷链食品相关本土新冠疫情均为冷链从业人员接触进口冷链食品或其外包装感染引起,且大部分（75%）引起了后续社区传播,但是在中国大陆集中监管仓建设等各种有力控制措施下,此类疫情数量和持续时间均呈下降趋势。     

预制混凝土U型槽在寒区渠道防渗中的应用

阐述了混凝土U型槽的防渗特点和在施工中应注意的问题。     

大塑性变形制备超细晶生物医用钛合金的研究进展

生物医用钛合金具有高强度、良好的耐蚀性能、较低的弹性模量、优异的生物相容性,已成为具有广阔应用前景的医用金属材料之一.与传统医用钛合金相比,超细晶医用钛合金具有更高的强度与更好的疲劳性能以及耐腐蚀性能.此外,超细晶钛合金可诱导骨组织向内生长,增加界面结合强度,加快骨修复进程,在硬组织修复材料领域具有广阔的应用前景.阐述了各种大塑性变形（Severe Plastic Deformation）法制备超细晶生物医用钛合金的研究状况与最新进展,指出了SPD法制备医用钛合金中存在的技术问题和发展方向,并展望了利用SPD法对生物医用钛合金改性将成为生物医用材料的研究热点.     

G-csF在急性粒细胞白血病化疗中的应用

重组人集落细胞刺激因子能够提高急性粒细胞白血病的缓解率,减少感染,为白血病的治愈创造了条件。     

剧烈塑性变形：不仅是晶粒细化

剧烈塑性变形在生产超细晶材料方面已经显示了巨大的潜力。虽然大量的研究集中在晶粒细化上,等通道转角挤压和高压扭转等剧烈塑性变形过程正在越来越多地被应用于其他领域诸如粉末固结,利用变形引发相变制作新颖结构与成分,获得多相及多尺度材料以及固态回收技术。本文引用我们近十年来的研究成果以介绍剧烈塑性变形在晶粒细化之外的诸多应用。特别是利用剧烈塑性变形颗粒固结来制取大块铝、钛、铝/钛双相合金和铝基纳米复合材料,利用机械激活和强制合金化来获得包括面心立方在内的新型钛结构,利用剧烈塑性变形引发的相变来制备纳米晶beta钛合金,以及利用等通道转角挤压来固态回收钛合金切削料。最后,对存在的挑战和机会进行了探讨。     

增强IVR有效性的堆内注水策略研究

熔融物堆内滞留（IVR）是一项核电厂重要的严重事故管理措施,通过将熔融物滞留在压力容器内,以保证压力容器完整性,并防止某些可能危及安全壳完整性的堆外现象。对于高功率和熔池中金属量相对不足的反应堆,若下封头形成3层熔池结构,则其顶部薄金属层导致的聚焦效应可能对压力容器完整性带来更大的威胁。本文考虑通过破口倒灌及其他工程措施实现严重事故下熔池顶部水冷却,建立熔池传热模型,分析顶部注水的带热能力,建立事件树,分析顶部注水措施的成功概率及IVR的有效性。结果表明,通过压力容器内外同时水冷熔融物,能显著增强IVR措施的有效性。     

Outcome among patients with acute renal failure needing continuous renal replacement therapy: A single center study

Outcome of acute renal failure (ARF) and use of continuous renal replacement therapy (CRRT) have shown a consistently high mortality. (1) Evaluate the short-term patient survival. (2) Evaluate dialysis-free survival. (3) Evaluate risk factors associated with overall survival and the continued need for intermittent dialysis. We identified adults (≥18 years) needing CRRT, treated in the critical care units of Froedtert Medical and Lutheran Hospital from January 1, 2003 till December 31, 2005. Patients were divided into two major groups needing CRRT, end stage renal disease (ESRD) (chronic dialysis) and non-ESRD with ARF. Continuous renal replacement therapy was performed with an average of 2 L replacement fluid exchanges/h. Sigma stat software was used for analysis. Comparison was done for noncontinuous variables by chi-square and t test for categorical and continuous variables, respectively. A total of 110 (ESRD 24/non-ESRD 86) patients received CRRT during study period. Over all in-hospital mortality among non-ESRD patients was 63% vs. 46% for ESRD. Among non-ESRD patients who survived, 47% needed intermittent hemodialysis on intensive care unit discharge and 28% continued to need hemodialysis at last follow-up. Among non-ESRD patients alive at discharge, those who were dialysis dependent on last follow-up were older (64.5) than those who did not require dialysis on last follow-up (58.4) P=0.347. Non-ESRD patients who died were in the hospital for an average of 17.5 days compared with 29 days for those who were discharged from the hospital. Patients with ARF needing CRRT have high in-hospital mortality. A significant percentage of patients remained dialysis dependant on last follow-up.     

Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy

Immunotherapy is a milestone in the treatment of poor-prognosis pediatric acute lymphoblastic leukemia (ALL) and is expected to improve treatment outcomes and reduce doses of conventional chemotherapy without compromising the effectiveness of the therapy. However, both chemotherapy and immunotherapy cause side effects, including neurological ones. Acute neurological complications occur in 3.6–11% of children treated for ALL. The most neurotoxical chemotherapeutics are L-asparaginase (L-ASP), methotrexate (MTX), vincristine (VCR), and nelarabine (Ara-G). Neurotoxicity associated with methotrexate (MTX-NT) occurs in 3–7% of children treated for ALL and is characterized by seizures, stroke-like symptoms, speech disturbances, and encephalopathy. Recent studies indicate that specific polymorphisms in genes related to neurogenesis may have a predisposition to MTX toxicity. One of the most common complications associated with CAR T-cell therapy is immune effector cell-associated neurotoxicity syndrome (ICANS). Mechanisms of neurotoxicity in CAR T-cell therapy are still unknown and may be due to disruption of the blood–brain barrier and the effects of elevated cytokine levels on the central nervous system (CNS). In this review, we present an analysis of the current knowledge on the mechanisms of neurotoxicity of standard chemotherapy and the targeted therapy in children with ALL.